On Tuesday, the Coalition for Epidemic Preparedness Innovations (CEPI) announced the latest award under its USD 200 m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses.
CEPI will provide funding of up to USD19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium comprising Bharat Biotech International Ltd (BBIL), India, the University of Sydney, Australia and ExcellGene SA, Switzerland.
CEPI’s funding will support the consortium as it seeks to establish preclinical and clinical proof of concept for an adjuvanted subunit vaccine designed to provide broad protection against all known SARS-CoV-2 variants of concern, as well as future variants of the virus which have not yet emerged. CEPI will fund the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.
In this new vaccine design, modified trimeric spike immunogens will be produced in a robust and scalable process with high purity and yield at low cost, based on a biomanufacturing approach that has provided significant quantities of protein therapeutics to the world. This strategy could also be used to enable rapid development of broadly protective vaccines against other beta coronaviruses, as well as vaccines against Disease X–unknown pathogens with pandemic potential that emerge in the future.
CEPI is committed to the principle of equitable access to the vaccines it funds. Under the terms of the funding agreement, the consortium partners have committed to achieving equitable access to the outputs of this project, in line with CEPI’s Equitable Access Policy.
CEO of CEPI, Dr Richard Hatchett said, that as repeated waves of COVID-19 infection remind us, we will be living alongside the virus for many years to come. The threat of a new variant emerging that might evade the protection of our current vaccines is real.
“Investing in R&D for variant-proof SARS-CoV-2 vaccines is a global health security imperative. Our partnership with Bharat Biotech, University of Sydney and ExcellGene will advance the development of a vaccine candidate to protect against future variants of COVID-19, potentially contributing to the long-term control of the virus,” he added.
Chairman and Managing Director of BBIL Dr Krishna Ella said, “BBIL has successfully commercialized a universal COVID-19 vaccine for adults and children. While the current generation of vaccines is safe and effective against currently known variants, it is imperative that we focus on innovation for multi-epitope vaccines, where a single vaccine can protect against all future variants. Our expertise in product development and innovation, especially with novel adjuvants and platform technologies will add to the strong partnership with CEPI, ExcellGene, and the University of Sydney.”
In this regard, James Triccas, Professor at Sydney Institute for Infectious Diseases, The University of Sydney, said that the institute is delighted to partner with CEPI to progress its platform for the development of broadly protective COVID-19 vaccines.
He said, “Our mission is to deliver safe, affordable and highly effective vaccines to combat existing and future SARS-CoV-2 variants, and our international consortium is well placed to achieve this goal. The University of Sydney will provide a framework for pre-clinical assessment of vaccine candidates, together with access to Australia’s world-class early phase clinical trial community.”
CEO of ExcellGene, Dr Maria J. Wurm, said, “Our technological platform for innovative protein designs was used in the past to identify and manufacture an antigen for an Ebola candidate vaccine, resulting in sterilizing immunity in preclinical challenge models. For the current COVID-19 project we are using similar approaches to generate numerous antigen preparations derived from spike protein variants of SARS-CoV-2, focussing eventually on the most promising antigen for vaccine purposes. Obtaining funding and scientific advice from CEPI to further our ongoing collaborations with the University of Sydney and Bharat Biotech is an exciting and most gratifying perspective and will, we hope, contribute towards the science for this and other novel protein-based vaccines.”
Strengthening our defences against coronaviruses
The world has made great advances in vaccine development against COVID-19, but variants of concern will continue to pose a threat to this progress as long as the virus continues to circulate. Vaccines have dramatically altered the course of the COVID-19 pandemic in countries that have access to them, but emerging variants that are more transmissible, more deadly, and/or can evade the protection provided by current vaccines could create significant challenges. Developing novel vaccines that target multiple variants of the SARS-CoV-2 virus and have the potential to generate immunity against all of them is therefore essential for the long-term control of the virus.
As illustrated by COVID-19, coronaviruses have devastating pandemic potential. The emergence of a coronavirus combining the transmissibility of COVID-19 with the lethality of SARS or MERS would be catastrophic, so developing vaccines that provide broad protection against the whole betacoronavirus genus is vital to our global health security. CEPI is working closely with partners to advance work in this area as quickly as possible.
The award announced today is the ninth programme to be funded by CEPI to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other beta coronaviruses. This work forms an important part of CEPI’s next 5-year plan which aims to reduce or even eliminate the future risk of pandemics and epidemics. (ANI)
Comments